Paclitaxel + reparixin

Paclitaxel + reparixin is a combination therapy under investigation primarily for metastatic breast cancer, especially triple-negative and HER2-negative subtypes. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis in rapidly dividing cells. Reparixin is an investigational small molecule that acts as a non-competitive allosteric inhibitor of the chemokine receptors C-X-C chemokine receptor type 1 (CXCR1) and C-X-C chemokine receptor type 2 (CXCR2), which are involved in the signaling of CXCL8 (interleukin 8). By blocking these receptors, reparixin targets cancer stem cells (CSCs) within tumors, potentially reducing tumor recurrence and metastasis. Preclinical studies have shown that this combination can reduce CSC populations more effectively than either agent alone. Clinical trials have demonstrated safety and tolerability for the combination with some evidence of durable responses in metastatic breast cancer patients[1][2][5][7].

Brand names

Taxol (for paclitaxel)

Other names

reparixinpaclitaxel